OmniAb, Inc. (OABI) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-04
How it makes money
Partners pay for technology access and for the success of the drugs they develop using its platform.
Partners pay upfront fees and service fees for research.
However, the most significant money comes from future successes.
This includes milestone payments and royalties on any products that eventually reach the market.
What protects it: the moat
Management claims it possesses the industry's most diverse host systems for creating human antibodies.
The company uses proprietary transgenic animals and artificial intelligence to identify antibodies.
It asserts that these biological systems provide a level of diversity that competitors cannot easily match.
What growth costs
It relies on third parties to provide the colonies and equipment needed for its research.
The filing does not specify the exact amount of capital required to maintain or grow its research efforts.
What could damage it
If partners fail to bring drugs to market, the company loses its most valuable revenue streams.
Because the most significant income depends on successful drug development, clinical failures at the partner level directly destroy the company's potential earnings.
About OmniAb, Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.